Zentalis Pharmaceuticals, Inc. (ZNTL) financial statements and ratios from SEC XBRL: revenue $0.00 (TTM), revenue growth -100.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $0.00 |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | -18.0% |
| FCF Growth (YoY) | -26.8% |
| Price / Book | 1.89 |
| FCF Yield | -47.1% |
| Altman Z-Score | -4.38 (distress) |
| Sector P/E (Healthcare) | 21.7 |
ZNTL overview · ZNTL earnings · ZNTL KPIs · ZNTL investor relations · ZNTL ownership · ZNTL peers · ZNTL filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.